Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 5/20 | 0.60 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356087 | 1.00 | TAOK1 (0.60) | TAOK1TAOK3CNR2KCNH2SCN9A | |
| SCHEMBL354944 | 0.87 | MCHR1 (0.47) | TAOK1TAOK3CNR2CA1CA2 | |
| SCHEMBL354945 | 0.87 | MCHR1 (0.47) | TAOK1TAOK3CNR2CA1CA2 | |
| SCHEMBL2813040 | 0.81 | RAB9A (0.62) | TP53 | |
| SCHEMBL2813850 | 0.81 | RAB9A (0.62) | TP53 | |
| SCHEMBL2813037 | 0.81 | RAB9A (0.62) | TP53 | |
| SCHEMBL10082902 | 0.80 | TAOK3 (0.56) | TAOK1TAOK3CNR2 | |
| SCHEMBL415259 | 0.79 | MCHR1 (0.54) | — | |
| SCHEMBL415260 | 0.79 | MCHR1 (0.54) | — | |
| SCHEMBL10082911 | 0.76 | MCHR1 (0.57) | TAOK1TAOK3CNR2KCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841290-B2 | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2014-09-23 | — | — | US | disclosed |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-2396300-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | PAH, MCHR1, DHPS | TAOK1 2034/4885TAOK3 1665/4885CNR2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.